Advertisement


Ursula A. Matulonis, MD, and Ignace Vergote, MD, PhD, on Cervical Cancer: Interim Results on Tisotumab Vedotin-tftv Plus Pembrolizumab

2022 ASCO Annual Meeting

Advertisement

Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, and Ignace Vergote, MD, PhD, of Belgium’s University Hospitals Leuven, discuss interim safety and efficacy results from a third dose-expansion cohort evaluating first-line tisotumab vedotin-tftv plus pembrolizumab in patients with recurrent or metastatic cervical cancer. Data on the combination showed durable antitumor activity with a manageable safety profile (Abstract 5507).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Ursula Matulonis: Ignace, it's great to see you. Congratulations on this abstract. I think it's one of the exciting abstracts of ASCO 2022, and thank you for presenting the results. So, tell us about this trial and about tisotumab vedotin and its mechanism of action. Ignace Vergote: Thank you for your compliment. The tisotumab vedotin is an antibody drug conjugate binding to tissue factor. Tissue factor is present in many tumors, but especially in cervical cancer. Almost always it's present. And like all antibody drug conjugates, it binds to tissue factor and then the active chemotherapy is monomethyl or Restatin-E, which is a chemotherapy which is used often in ADCs. Once it's incorporated in the cell, the antibody and the drug splits and cell death is the result, which also results in activation of the T-cells, which are promoted due to the apoptosis. This is also the reason why a combination with PD-L1 blockers is very interesting because, of course, in this way we get even a stronger immunological effect in addition to the chemotherapeutic effect. Ursula Matulonis: So, tell us about the three arms that you presented, and also the really exciting results that you presented that's come out of those arms. Ignace Vergote: Yeah. So the three arms which we have presented here is two in first line, recurrent cervical cancer, or advanced cervical cancer, stage four, usually. One cohort with tisotumab vedotin and carboplatin and one cohort with tisotumab vedotin and pembro. And the other is second line or third line. It's about three, three quarter second line, and the rest third line with tisotumab vedotin and pembrolizumab again. Ursula Matulonis: And tell us about, the results are quite striking in terms of the overall response rates. Ignace Vergote: Yes. In first line with tisotumab vedotin and carboplatin, we have a response rate of 55%, which is good. That's without pembro, without the bevacizumab. Like, when we compare to keynote A26, we have to take into account it's only two drugs. And very similar for, tisotumab vedotin and pembro and first line 41% response. And what is very interesting is that the response in the two cohorts with pembro is very long. We have follow-up of one and a half year almost. And the medium duration of response in the TV pembro is not even reached. And that's of course, something which we know with IOs. Also with siniprimot and second line. The responses, if there are responses, is very long. That a combination of the tisotumab vedotin and pembro, you see a higher response rate and a long response rate. More than one year. Ursula Matulonis: And I think most of the patients on the Pembro arm were PD-L1 positive? Ignace Vergote: Yes. That was about, depending on the cohort, between 85% and 91%. So, there were PD-L1 positive. We didn't select it for them, but we know that in cervical cancer about 90% is PD-L1 positive. So, that's concordant. Ursula Matulonis: It's very, it's very impressive results. So, tell us a little bit about the toxicities of tizonumab and then if you saw any unusual toxicities, when, when putting this drug together with either carboplatin or with, with pembro. Ignace Vergote: Well, I've been involved in tisotumab vedotin now for six, seven years already. I did the first in humans. The phase one I presented at ESMO, I think in 2017. The monotherapy, and then the consolidation trial, which led to the fast track approval of the monotherapy in second line. And in the beginning, the eye toxicity was more of a problem, especially when we gave tisotumab vedotin weekly. There was also cohort, but we learned how to treat this eye toxicity and how to prevent it with eye drops, with cooling pads on the eyes during the infusion. And so in this study, we have, I think, depending on the cohort, but we have about 3% grade three eye toxicity, but the main toxicities are grade one and two and quite quickly reversible now with these precautions. So, for the peripheral neuropathy, indeed, we see this as well. But, as you know we all have a lot of experience with paclitaxel and when I compare it, it's less and later. It's especially patients who are treated very long. We have been treating patients up to one year with tisotumab vedotin, and then you see it. Sometimes earlier, but it's mainly a late effect. And little bit different characteristics compared with what we know from paclitaxel. Ursula Matulonis: Next steps for tisotumab and cervical cancer? Ignace Vergote: Well, we are doing with GOG foundation, the ENGOT Cervix 12, which is a trial in second line with monotherapy and randomized phase three, which is running very well compared with the classical chemotherapies. So this is one thing. And then the other thing, of course, with these results, which we have presented here, we are doing a new cohort with the, with the triplet and the quadruplet. We have also presented that as a tip here, meaning tisotumab vedotin, carboplatin, pembro, and Bev. Or the triplets, if Bev is contraindicated. So, and this is of course the preparation of a first line trial as well. Ursula Matulonis: Congratulations. That makes perfect sense. It's it's a really active drug and thank you for your really significant role in, in starting the trials and getting to this time point for a cancer that really hasn't had much in terms of movement forward in terms of new treatments. And advances. So, so thank you so much. Ignace Vergote: Thank you.

Related Videos

Head and Neck Cancer

Sue S. Yom, MD, PhD, on Oropharyngeal Cancer and the Feasibility of a Cell-Free DNA Plasma Assay

Sue S. Yom, MD, PhD, of the University of California, San Francisco, discusses a translational analysis from the NRG-HN002 study. This phase II trial established the feasibility of the tumor tissue–modified viral (TTMV) human papillomavirus DNA assay in clinical trial specimens. The goal is to use such an assay to measure tumor volume, levels of TTMV over the course of treatment, and the association of TTMV to treatment outcomes (Abstract 6006).

 

Pancreatic Cancer

Pamela L. Kunz, MD, on Pancreatic Neuroendocrine Tumors: A Final Analysis of Temozolomide or Temozolomide Plus Capecitabine

Pamela L. Kunz, MD, of the Yale University School of Medicine, discusses new findings from the ECOG-ACRIN E2211 trial, which showed the longest progression-free survival and highest response rates with temozolomide plus capecitabine reported to date for patients with pancreatic neuroendocrine tumors. The presence of a deficiency of MGMT, the drug-resistance gene, was associated with greater odds of an objective response (Abstract 4004).

Michael J. Overman, MD, and Takayuki Yoshino, PhD, MD, on Colorectal Cancer: Phase III Data on Panitumumab or Bevacizumab Plus mFOLFOX6

Michael J. Overman, MD, of The University of Texas MD Anderson Cancer Center, and Takayuki Yoshino, PhD, MD, of the National Cancer Center Hospital East, Japan, discuss results from the PARADIGM trial, the first prospective study to test the superiority of panitumumab vs bevacizumab in combination with standard doublet first-line chemotherapy for patients with RAS wild-type and left-sided metastatic colorectal cancer. The study showed that panitumumab improved overall survival in combination with mFOLFOX6, which may establish a standard first-line combination regimen for this population (Abstract LBA1).

Lung Cancer
Immunotherapy

Gilberto de Lima Lopes, Jr, MD, MBA, and Karen L. Reckamp, MD, on NSCLC: Overall Survival Results With Ramucirumab Plus Pembrolizumab vs Standard of Care

Gilberto de Lima Lopes, Jr, MD, MBA, of the Sylvester Comprehensive Cancer Center at the University of Miami, and Karen L. Reckamp, MD, of Cedars-Sinai Medical Center, discuss phase II findings from substudy S1800A of the Lung-MAP protocol. The data showed that ramucirumab and pembrolizumab improved overall survival compared with the standard of care for patients with advanced non–small cell lung cancer who were previously treated with immunotherapy and platinum-based chemotherapy (Abstract 9004).

 

Leukemia

Courtney D. DiNardo, MD, MSCE, and Stéphane de Botton, MD, PhD, on AML: New Data on IDH2-Mutant Alleles, Enasidenib, and Conventional Care

Courtney D. DiNardo, MD, MSCE, of The University of Texas MD Anderson Cancer Center, and Stéphane de Botton, MD, PhD, of Institut Gustave Roussy, discuss phase III findings from the IDHENTIFY trial, which showed that mutational burden and co-mutational profiles differed between patients with relapsed or refractory acute myeloid leukemia that exhibited IDH2-R140 and IDH2-R172 mutations. Enasidenib improved survival outcomes for patients with IDH2-R172 mutations: median overall survival and 1-year survival rates were approximately double those in the conventional care arm (Abstract 7005).

Advertisement

Advertisement




Advertisement